SCHEMBL6860610

SCHEMBL6860610

O=S(=O)(O)Cc1cc(Br)c(Oc2ccc3[nH]cc(S(=O)(=O)c4ccncc4)c3c2)c(Br)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.43
SMN1; SMN2 Q16637 4/20 0.38
KDM4E B2RXH2 2/20 0.38
HTT P42858 3/20 0.37
LMNA P02545 2/20 0.37
POLB P06746 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
THRA P10827 5/20 0.36
THRB P10828 5/20 0.36
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
HDAC3 O15379 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC7 Q8WUI4 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC10 Q969S8 1/20 0.35
HDAC11 Q96DB2 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6514290 0.90 MAPT (0.45) MAPTSMN1; SMN2KDM4EHTTLMNA
SCHEMBL6532229 0.89 MAPT (0.43) MAPTSMN1; SMN2KDM4EHTTLMNA
SCHEMBL6523435 0.89 MAPT (0.48) MAPTSMN1; SMN2KDM4EHTTLMNA
SCHEMBL6514370 0.89 SMN1; SMN2 (0.50) MAPTSMN1; SMN2KDM4EHTTLMNA
SCHEMBL6520241 0.89 MAPT (0.56) MAPTSMN1; SMN2KDM4EHTTLMNA
SCHEMBL6516325 0.89 SMN1; SMN2 (0.50) MAPTSMN1; SMN2KDM4EHTTLMNA
SCHEMBL6520056 0.89 MAPT (0.59) MAPTSMN1; SMN2KDM4EHTTLMNA
SCHEMBL6514265 0.88 MAPT (0.44) MAPTSMN1; SMN2KDM4EHTTLMNA
SCHEMBL6513862 0.88 THRB (0.44) MAPTTHRATHRBHDAC3HDAC4
SCHEMBL6520130 0.86 THRA (0.47) MAPTSMN1; SMN2KDM4EHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6794406-B2 FOR THERAPY AND PROPHYLAXIS OF ARTERIOSCLEROSIS AND HYPERCHOLESTEROLAEMIA BAYER AKTIENGESELLSCHAFT (DE) 2004-09-21 US disclosed
US-20030078288-A1 Indole derivatives BAYER AKTIENGESELLSCHAFT (DE) 2003-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078288-A1 Indole derivatives IDO1, IDO2, TPH2 MAPT 839/4885SMN1; SMN2 4749/4885KDM4E 1199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.